> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Keros Stock Soars 9% After $5 Million Buyback Announcement
- URL: https://www.bullished.co/keros-stock-soars-9-after-5-million-buyback-announcement-e6aa9d05/
- Published: 2026-11-17T15:35:12.000Z
- Updated: 2026-11-17T15:35:12.000Z
- Description: A $20 million Takeda milestone payment preceded the authorization, but management can choose to purchase no shares.
- Author: Matteo Parrino
- Tags: Markets, KROS, Industry: Healthcare

[Keros Therapeutics](https://www.bullished.co/tag/kros/), which develops drugs for blood and muscle disorders, soared 8.8% to $10.91 in Tuesday trading, as of 10:33 AM ET, adding $17 million in market value. The gain followed Monday's announcement of a [$5 million buyback](https://www.sec.gov/Archives/edgar/data/1664710/000166471026000072/exhibit991111626pr.htm?ref=bullished.co) authorization in a company release.

## Takeda Payment Precedes The Buyback

Keros received a [$20 million payment](https://www.sec.gov/Archives/edgar/data/1664710/000166471026000072/exhibit991111626pr.htm?ref=bullished.co) from Takeda, its licensing partner for elritercept, after patients began receiving the drug in a myelofibrosis trial. That development milestone preceded the repurchase authorization.

Management controls whether and when to spend the money. It can [halt the program](https://www.sec.gov/Archives/edgar/data/0001664710/000166471026000072/kros-20261116.htm?ref=bullished.co) or choose to buy no shares, so the authorization leaves actual purchases at its discretion.

Keros was on pace Tuesday for its biggest one-day gain since May 20\. Its total market value was about $214 million in Tuesday trading.

## Profit Returned, Shares Still Slid

Keros shares were down 51% for the year at Monday's close, compared with a 9% gain for the S&P 500\. The decline persisted despite a return to quarterly profit.

Third-quarter [net income reached](https://www.sec.gov/Archives/edgar/data/0001664710/000166471026000065/exhibit991q32026.htm?ref=bullished.co) $14.2 million, against a $7.3 million loss a year earlier, according to the company's results release published Thursday, November 5\. Keros attributed the improvement chiefly to revenue from its Takeda license.

Research and development spending rose to $20.5 million from $19.5 million a year earlier. Keros attributed the increase to work advancing its drug pipeline, partly offset by lower elritercept spending as activities shifted to Takeda during 2025.

Administrative spending fell to $6.7 million from $10.1 million, which the company attributed primarily to lower pay costs and professional fees. Cash and cash equivalents stood at $259.5 million on September 30, compared with $287.4 million at the end of 2025\. At the results update, management expected that cash to cover operations and capital spending into the second half of 2028.

## Muscle And Blood Treatments Advance

Keros develops protein-based treatments targeting faulty TGF-β signaling, a system involved in tissue growth and repair. Its drugs remain in development and are not yet approved for sale.

Its neuromuscular work centers on rinvatercept for Duchenne muscular dystrophy and amyotrophic lateral sclerosis. Elritercept targets low blood cell counts in myelodysplastic syndromes and myelofibrosis. Under the license effective January 16, 2025, Takeda develops, manufactures and commercializes elritercept outside mainland China, Hong Kong and Macau.

Patients began receiving rinvatercept in the mid-stage Duchenne trial in September. Keros expects [initial trial data](https://www.sec.gov/Archives/edgar/data/0001664710/000166471026000065/exhibit991q32026.htm?ref=bullished.co) in the first half of 2027.

Keros also selected KER-206 for further investigation before human testing. The company presented research on it in October at the American Society for Bone and Mineral Research 2026 Annual Meeting. Keros believes the candidate could increase bone mass and improve skeletal strength in disorders involving abnormal bone loss.

The $5 million authorization gives Keros room to repurchase shares; management retains the choice over whether that money is spent.

### Sources

- [Document](https://www.sec.gov/Archives/edgar/data/1664710/000166471026000072/exhibit991111626pr.htm?ref=bullished.co) — sec.gov
- [Keros Therapeutics Announces Additional $5 Million Share](https://www.globenewswire.com/news-release/2026/11/16/3404089/0/en/keros-therapeutics-announces-additional-5-million-share-repurchase-authorization.html?ref=bullished.co) — globenewswire.com
- [The company's filing (Keros Therapeutics)](https://www.sec.gov/Archives/edgar/data/0001664710/000166471026000072/kros-20261116.htm?ref=bullished.co) — SEC filing
- [Keros Therapeutics — Form 10-Q for the quarter ended 2026-09-30 (quarterly results)](https://www.sec.gov/Archives/edgar/data/1664710/000166471026000066/kros-20260930.htm?ref=bullished.co) — SEC EDGAR
- [Keros Therapeutics — earnings release (Form 8-K, Item 2.02), filed 2026-11-05](https://www.sec.gov/Archives/edgar/data/0001664710/000166471026000065/exhibit991q32026.htm?ref=bullished.co) — SEC EDGAR

### More on Keros Therapeutics

- [Keros Therapeutics Authorizes Up To $5 Million In Buybacks Following $20 Million Drug Payment](https://www.bullished.co/keros-therapeutics-authorizes-up-to-5-million-in-buybacks-following-20-million-drug-f978de1e/)
- [Keros Turns A $14.2 Million Quarterly Profit As Takeda License Revenue Reaches $40 Million](https://www.bullished.co/keros-turns-a-14-2-million-quarterly-profit-as-takeda-license-revenue-reaches-40-million-59e2970c/)
- [Keros Therapeutics Triggers $20 Million Takeda Milestone — Separate $20 Million Payment Received](https://www.bullished.co/keros-therapeutics-triggers-20-million-takeda-milestone-separate-20-million-payment-291a9b44/)

[All Keros Therapeutics (KROS) coverage →](https://www.bullished.co/tag/kros/)